News Release | Contact: | |
For Immediate Release | Anna Austin, EVP, Corporate Communications (636) 534-2271 Email: investor.relations@tlcvision.com |
TLCVisionReports First Quarter 2007 Financial Results;
Procedure Volumes Increase 7% In Refractive Centers
ST. LOUIS, MO, May 10, 2007: TLC Vision Corporation (NASDAQ:TLCV; TSX:TLC), North America’s premier eye care services company, today announced its financial results for the first quarter ended March 31, 2007. All dollar amounts are expressed in U.S. currency and results are reported in accordance with U.S. generally accepted accounting principles (U.S. GAAP) unless otherwise noted.
Editor’s Note: “Operating Business” (or “Operating”) is defined as TLCVision’s activities excluding the impact of the AMD segment, principally represented by our investment in OccuLogix, Inc. To provide maximum transparency for investors, Operating Business financial results are listed separately from consolidated results in this press release.
“In the first quarter, TLCVision saw solid overall revenue growth and strong procedure volume increases in our branded Refractive Centers business,” said Jim Wachtman, President and Chief Executive Officer. “In our centers business, we are delivering growth across all of our patient acquisition channels as we predicted when we first announced our new strategy last Fall. As the result of process improvements implemented in 2006, our call center is capturing more of the leads and we are converting those leads at a higher rate, resulting in increased consultations and surgeries. With these positive trends continuing into the second quarter, we are experiencing renewed growth in our Refractive Centers business. This demonstrates our ability to successfully execute on our strategy and underscores our optimism about the future of our Company.”
FIRST QUARTER HIGHLIGHTS:
• | Refractive Centers procedure volume grew 7% overall with same store growth of 6%, both ahead of estimated 1.4% industry growth rate. |
• | 29 Refractive Centers converted to the new business model in March, with over 20% growth across a range of key metrics including leads and patient consult appointments, as well as growth in both optometric referrals and the total number of referring optometrists. |
• | 7% consolidated revenue growth. |
• | Earnings of $0.05 per share (consolidated) and $0.09 per share (operating business) even with increased marketing investment. |
• | Operating cash flow of $15.3 million ($0.22 per share), $1.5 million ahead of prior year. |
• | Tender Offer to repurchase up to 20 million shares announced, enhancing long term shareholder value. |
REVENUES
TLCVision’sfirst quarter net revenues were $83.2 million, an increase of over 7% from 2006.
Beginning in 2007, the Company has realigned its organization into three lines of business to more closely match our customers and delivery models, and to provide additional transparency into our operating results:
• | Refractive Centers includes the Company’s 78 centers that provide laser vision correction surgery, of which 67 centers are majority-owned and 11 centers are minority-owned. One new center, TLC Seattle, was opened in January. Total centers revenues were up 8% to $51.7 million (6% same store). Total procedures of 38,000, including minority-owned centers, were up 7% overall and up 6% on a same store basis. |
• | Doctor Services includes the Company’s refractive access, mobile cataract access, ambulatory surgery centers and practices, which more closely aligns these service offerings and leverages our extensive doctor relationships. Doctor Services revenues increased 4% to $25.9 million. Refractive access revenues were equal to prior year, even though procedure volume of 18,900 was 8% lower than prior year. Total mobile cataract access revenues of $8.9 million were 12% over prior year on higher cataract volumes and new offerings. Our ambulatory surgery center and practice businesses delivered revenue of $6.2 million, even with last year, as lower surgical volume was offset by a favorable mix of procedures. |
• | Eye Care consists primarily of the Company’s Vision Source optometric franchising business and its AMD segment (including the Company’s investment in OccuLogix, Inc.). Eye Care revenues grew 21% over prior year as a result of new franchises and higher fees per franchisee. |
Note that the unaudited, interim consolidated financial statements for the three months ended March 31, 2006 include certain reclassifications to conform with the business-line and segment classifications for the three months ended March 31, 2007.
EARNINGS
Consolidated: Net income for the first quarter was $3.5 million, which includes the ($2.5 million) loss from our investment in OccuLogix.
Operating Business: Net income from the Operating Business was $6.0 million or $0.09 per share. These results were $0.5 million ahead of 2006 on an as-reported basis. Embedded in the current year results is an effective tax rate of 14%, approximately 7% below the anticipated full year rate (a benefit of approximately $0.5 million).
STRONG CASH GENERATION
Operating cash flow in the first quarter was $15.3 million ($0.22 per share), up $1.5 million for the same period in 2006. The Company continues to maintain a strong financial position, with cash and short-term investments totaling $47.1 million.
“With aggressive strategies in place, we have established a solid springboard to take advantage of the enormous opportunities in our market segments,” said Jim Wachtman. “Our shareholders have been very patient while we developed the right approach for our Company to capitalize on these eye care opportunities, especially in our highest contributing Refractive Centers business, and now we are delivering on that approach. We believe this patience will be rewarded by the financial markets as we continue to execute on our robust strategies, driving results and furthering our leadership in this industry.”
CONFERENCE CALL
TLCVisioninvites all interested parties to participate in a conference call during which time the financial and operating results will be discussed. The call will be held today, at 10:30 a.m. Eastern Time. To participate, please dial 877-888-4605. International callers may dial 416-695-6622. The call will be broadcast live on the company’s web site atwww.tlcv.com under the “Webcasts” link in the Investor Relations section. In addition, the live webcast will be available at various other popular portals and financial web sites.
A replay of the conference call will be available until May 24, 2007. To access the replay, dial 888-509-0081(pass code: 643024). The call will also be archived on the company’s web site atwww.tlcv.com under the “Webcasts” link in the Investor Relations section.
About TLCVision
TLCVisionis North America’s premier eye care services company, providing eye doctors with the tools and technologies needed to deliver high-quality patient care. Through its centers management and technology access service models, and its managed care contracting strength, TLCVision maintains leading positions in Refractive, Cataract and Optometric Services markets. More information about TLCVisioncan be found on the website atwww.tlcv.com.
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934, which statements can be identified by the use of forward looking terminology, such as “may”, “will”, “expect”, ”intend”, “anticipate”, “estimate”, “predict”, “plans” or “continue” or the negative thereof or other variations thereon or comparable terminology referring to future events or results. The Company’s actual results could differ materially from those anticipated in these forward looking statements as a result of numerous factors, including the timing of expenditures, effects of competition, changes to pricing, acquisitions and expansion opportunities, any of which could cause actual results to vary materially from current results or TLCVision’s anticipated future results. See the Company’s reports filed with the Canadian Securities Regulators and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward looking statements. TLCVision assumes no obligation to update the information contained in this press release.
1
TLC VISION CORPORATION | ||||||||||||||||||||||||
CONSOLIDATING STATEMENTS OF OPERATIONS (UNAUDITED) | ||||||||||||||||||||||||
(In thousands, except per share amounts) | ||||||||||||||||||||||||
Three Months Ended March 31, 2007 | Three Months Ended March 31, 2006 | |||||||||||||||||||||||
| | |||||||||||||||||||||||
Results Before AMD | Results Before AMD | |||||||||||||||||||||||
Segment | AMD Segment | Total TLCVision | Segment | AMD Segment | Total TLCVision | |||||||||||||||||||
Revenues: | ||||||||||||||||||||||||
Refractive centers | $ | 51,704 | $ | — | $ | 51,704 | $ | 48,092 | $ | — | $ | 48,092 | ||||||||||||
Doctor services | 25,918 | — | 25,918 | 24,896 | — | 24,896 | ||||||||||||||||||
Eye care | 5,572 | — | 5,572 | 4,593 | — | 4,593 | ||||||||||||||||||
Total revenues | 83,194 | — | 83,194 | 77,581 | — | 77,581 | ||||||||||||||||||
Cost of revenues (excluding amortization): | ||||||||||||||||||||||||
Refractive centers | 34,197 | — | 34,197 | 31,997 | — | 31,997 | ||||||||||||||||||
Doctor services | 18,381 | — | 18,381 | 16,759 | — | 16,759 | ||||||||||||||||||
Eye care | 2,475 | — | 2,475 | 1,974 | 1,659 | 3,633 | ||||||||||||||||||
Total cost of revenues (excluding amortization) | 55,053 | — | 55,053 | 50,730 | 1,659 | 52,389 | ||||||||||||||||||
Gross profit (loss) | 28,141 | — | 28,141 | 26,851 | (1,659 | ) | 25,192 | |||||||||||||||||
General and administrative | 9,930 | — | 9,930 | 9,068 | 1,759 | 10,827 | ||||||||||||||||||
Marketing and sales | 8,435 | — | 8,435 | 6,802 | 169 | 6,971 | ||||||||||||||||||
Research and development, clinical and regulatory | — | — | — | — | 1,475 | 1,475 | ||||||||||||||||||
Amortization of intangibles | 792 | — | 792 | 864 | — | 864 | ||||||||||||||||||
Other expenses, net | 438 | — | 438 | (357 | ) | 849 | 492 | |||||||||||||||||
Total operating costs | 19,595 | — | 19,595 | 16,377 | 4,252 | 20,629 | ||||||||||||||||||
Operating income (loss) | 8,546 | — | 8,546 | 10,474 | (5,911 | ) | 4,563 | |||||||||||||||||
Interest income | 568 | — | 568 | 647 | 366 | 1,013 | ||||||||||||||||||
Interest expense | (440 | ) | — | (440 | ) | (538 | ) | — | (538 | ) | ||||||||||||||
Minority interests | (2,539 | ) | — | (2,539 | ) | (2,529 | ) | 2,715 | 186 | |||||||||||||||
Earnings (losses) from equity investments | 811 | (2,517 | ) | (1,706 | ) | 923 | — | 923 | ||||||||||||||||
Income (loss) before income taxes | 6,946 | (2,517 | ) | 4,429 | 8,977 | (2,830 | ) | 6,147 | ||||||||||||||||
Income tax expense | (951 | ) | — | (951 | ) | (3,435 | ) | — | (3,435 | ) | ||||||||||||||
Net income (loss) | $ | 5,995 | $ | (2,517 | ) | $ | 3,478 | $ | 5,542 | $ | (2,830 | ) | $ | 2,712 | ||||||||||
Earnings (loss) per share — diluted | $ | 0.09 | $ | (0.04 | ) | $ | 0.05 | $ | 0.08 | $ | (0.04 | ) | $ | 0.04 | ||||||||||
Weighted average number of common shares outstanding — diluted | 69,651 | 69,651 | 69,651 | 69,550 | 69,550 | 69,550 | ||||||||||||||||||
Note: The AMD segment includes the Company’s interest in OccuLogix, Inc. | ||||||||||||||||||||||||
TLC VISION CORPORATION | ||||||||||||||||||||||||
CONSOLIDATING BALANCE SHEETS | ||||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||
March 31, 2007 | ||||||||||||||||||||||||
(Unaudited) | December 31, 2006 | |||||||||||||||||||||||
Results Before AMD | Results Before AMD | AMD Segment | ||||||||||||||||||||||
Segment | AMD Segment | Total TLCVision | Segment (Unaudited) | (Unaudited) | Total TLCVision | |||||||||||||||||||
ASSETS | ||||||||||||||||||||||||
Current assets | ||||||||||||||||||||||||
Cash and cash equivalents | $ | 34,972 | $ | — | $ | 34,972 | $ | 28,917 | $ | — | $ | 28,917 | ||||||||||||
Short-term investments | 12,100 | — | 12,100 | 11,575 | — | 11,575 | ||||||||||||||||||
Accounts receivable, net | 20,986 | — | 20,986 | 19,315 | — | 19,315 | ||||||||||||||||||
Deferred tax asset | 9,614 | — | 9,614 | 7,153 | — | 7,153 | ||||||||||||||||||
Prepaid expenses, inventory and other | 13,623 | — | 13,623 | 13,911 | — | 13,911 | ||||||||||||||||||
Total current assets | 91,295 | — | 91,295 | 80,871 | — | 80,871 | ||||||||||||||||||
Restricted cash | 1,035 | — | 1,035 | 1,035 | — | 1,035 | ||||||||||||||||||
Investments and other assets | 23,788 | 11,845 | 35,633 | 24,495 | 14,362 | 38,857 | ||||||||||||||||||
Goodwill | 92,770 | — | 92,770 | 96,148 | — | 96,148 | ||||||||||||||||||
Other intangible assets, net | 19,644 | — | 19,644 | 20,503 | — | 20,503 | ||||||||||||||||||
Fixed assets, net | 58,306 | — | 58,306 | 56,888 | — | 56,888 | ||||||||||||||||||
Total assets | $ | 286,838 | $ | 11,845 | $ | 298,683 | $ | 279,940 | $ | 14,362 | $ | 294,302 | ||||||||||||
LIABILITIES | ||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||
Accounts payable | $ | 12,158 | $ | — | $ | 12,158 | $ | 12,314 | $ | — | $ | 12,314 | ||||||||||||
Accrued liabilities | 20,048 | — | 20,048 | 20,231 | — | 20,231 | ||||||||||||||||||
Current maturities of long-term debt | 8,413 | — | 8,413 | 8,311 | — | 8,311 | ||||||||||||||||||
Total current liabilities | 40,619 | — | 40,619 | 40,856 | — | 40,856 | ||||||||||||||||||
Long-term debt, less current maturities | 14,890 | — | 14,890 | 15,122 | — | 15,122 | ||||||||||||||||||
Other long-term liabilities | 4,370 | — | 4,370 | 4,442 | — | 4,442 | ||||||||||||||||||
Minority interests | 14,765 | — | 14,765 | 14,583 | — | 14,583 | ||||||||||||||||||
Total liabilities | 74,644 | — | 74,644 | 75,003 | — | 75,003 | ||||||||||||||||||
STOCKHOLDERS’ EQUITY | ||||||||||||||||||||||||
Common stock | 420,284 | 30,366 | 450,650 | 419,767 | 30,366 | 450,133 | ||||||||||||||||||
Option and warrant equity | 1,801 | — | 1,801 | 1,806 | — | 1,806 | ||||||||||||||||||
Accumulated deficit | (209,891 | ) | (18,521 | ) | (228,412 | ) | (216,636 | ) | (16,004 | ) | (232,640 | ) | ||||||||||||
Total stockholders’ equity | 212,194 | 11,845 | 224,039 | 204,937 | 14,362 | 219,299 | ||||||||||||||||||
Total liabilities and stockholders’ equity | $ | 286,838 | $ | 11,845 | $ | 298,683 | $ | 279,940 | $ | 14,362 | $ | 294,302 | ||||||||||||
Note: The AMD segment includes the Company’s interest in OccuLogix, Inc. | ||||||||||||||||||||||||
TLC VISION CORPORATION | ||||||||||||||||||||||||
CONSOLIDATING STATEMENTS OF CASH FLOWS (UNAUDITED) | ||||||||||||||||||||||||
(In thousands, except per share amounts) | ||||||||||||||||||||||||
Three Months Ended March 31, 2007 | Three Months Ended March 31, 2006 | |||||||||||||||||||||||
| | |||||||||||||||||||||||
Results Before AMD | Results Before AMD | |||||||||||||||||||||||
Segment | AMD Segment | Total TLCVision | Segment | AMD Segment | Total TLCVision | |||||||||||||||||||
OPERATING ACTIVITIES | ||||||||||||||||||||||||
Net income (loss) | $ | 5,995 | $ | (2,517 | ) | $ | 3,478 | $ | 5,542 | $ | (2,830 | ) | $ | 2,712 | ||||||||||
Adjustments to reconcile net income (loss) to net cash from operating activities: | ||||||||||||||||||||||||
Depreciation and amortization | 4,389 | — | 4,389 | 3,758 | 34 | 3,792 | ||||||||||||||||||
Reimbursements from investments in research and development | ||||||||||||||||||||||||
arrangements | — | — | — | (300 | ) | — | (300 | ) | ||||||||||||||||
Minority interests | 2,539 | — | 2,539 | 2,529 | (2,715 | ) | (186 | ) | ||||||||||||||||
(Earnings) losses from equity investments | (811 | ) | 2,517 | 1,706 | (923 | ) | — | (923 | ) | |||||||||||||||
Deferred taxes | 851 | — | 851 | 2,131 | — | 2,131 | ||||||||||||||||||
Excess tax benefits from stock-based compensation expense | — | — | — | (1,710 | ) | — | (1,710 | ) | ||||||||||||||||
Loss (gain) on sales and disposals of fixed assets | (88 | ) | — | (88 | ) | 32 | 29 | 61 | ||||||||||||||||
Write-down of OccuLogix, Inc. inventory | — | — | — | — | 1,625 | 1,625 | ||||||||||||||||||
Non-cash compensation expense | 390 | — | 390 | 426 | 186 | 612 | ||||||||||||||||||
Other | 15 | — | 15 | — | 26 | 26 | ||||||||||||||||||
Changes in operating assets and liabilities, net of acquisitions and dispositions: | 2,019 | — | 2,019 | 2,344 | (1,225 | ) | 1,119 | |||||||||||||||||
Cash from operating activities | 15,299 | — | 15,299 | 13,829 | (4,870 | ) | 8,959 | |||||||||||||||||
INVESTING ACTIVITIES | ||||||||||||||||||||||||
Purchases of fixed assets | (3,671 | ) | — | (3,671 | ) | (2,349 | ) | — | (2,349 | ) | ||||||||||||||
Proceeds from sales of fixed assets | 243 | — | 243 | 26 | — | 26 | ||||||||||||||||||
Distributions and loan payments received from equity investments | 1,431 | — | 1,431 | 1,333 | — | 1,333 | ||||||||||||||||||
Reimbursements from investments in research and development | ||||||||||||||||||||||||
arrangements | — | — | — | 300 | — | 300 | ||||||||||||||||||
Acquisitions and equity investments | (2,718 | ) | — | (2,718 | ) | (1,474 | ) | — | (1,474 | ) | ||||||||||||||
Proceeds from sales of short-term investments | 3,225 | — | 3,225 | — | 9,925 | 9,925 | ||||||||||||||||||
Purchases of short-term investments | (3,750 | ) | — | (3,750 | ) | (1,650 | ) | — | (1,650 | ) | ||||||||||||||
Other | (10 | ) | — | (10 | ) | 14 | (71 | ) | (57 | ) | ||||||||||||||
Cash from investing activities | (5,250 | ) | — | (5,250 | ) | (3,800 | ) | 9,854 | 6,054 | |||||||||||||||
FINANCING ACTIVITIES | ||||||||||||||||||||||||
Restricted cash movement | — | — | — | (35 | ) | — | (35 | ) | ||||||||||||||||
Principal payments of debt financing and capital leases | (1,926 | ) | — | (1,926 | ) | (1,071 | ) | — | (1,071 | ) | ||||||||||||||
Proceeds from debt financing | 167 | — | 167 | 83 | — | 83 | ||||||||||||||||||
Excess tax benefits from stock-based compensation expense | — | — | — | 1,710 | — | 1,710 | ||||||||||||||||||
Distributions to minority interests | (2,357 | ) | — | (2,357 | ) | (2,184 | ) | — | (2,184 | ) | ||||||||||||||
Proceeds from issuances of common stock | 122 | — | 122 | 257 | — | 257 | ||||||||||||||||||
Proceeds from issuances of OccuLogix, Inc. stock | — | — | — | — | 233 | 233 | ||||||||||||||||||
Cash from financing activities | (3,994 | ) | — | (3,994 | ) | (1,240 | ) | 233 | (1,007 | ) | ||||||||||||||
Net increase in cash and cash equivalents during the period | 6,055 | — | 6,055 | 8,789 | 5,217 | 14,006 | ||||||||||||||||||
Cash and cash equivalents, beginning of period | 28,917 | — | 28,917 | 22,122 | 9,607 | 31,729 | ||||||||||||||||||
Cash and cash equivalents, end of period | $ | 34,972 | $ | — | $ | 34,972 | $ | 30,911 | $ | 14,824 | $ | 45,735 | ||||||||||||
Operating cash flow per diluted share | $ | 0.22 | $ | — | $ | 0.22 | $ | 0.20 | $ | (0.07 | ) | $ | 0.13 | |||||||||||
Note: The AMD segment includes the Company’s interest in OccuLogix, Inc. |
2